RxDoctor Payments Data

Ashley Taylor

Nurse Practitioner · Milwaukee, WINPI 1477169837

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $6,045 of the $9,104 with a category attached, or 66.4%. Eisai Inc. accounts for 70.1% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2022 at $7,237 and has fallen 98.0% since, to $144 in 2023. Among nurse practitioner clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,104in general payments, 2019–2025

Across 156 payments — averaging $58.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$6K
  • AbbVie$434
  • AstraZeneca$381
  • Daiichi Sankyo Inc.$352
  • Lilly USA, LLC$203
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$194
  • plus $1K from 20 others

What the payments were for

  • Consulting fees$6,04566%
  • Travel & lodging$2953%
  • Food & beverage$2,75730%
  • Education$70%

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,104 in reported general payments places this provider in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$30,579
Medicare patients
159
Services billed
394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$22,777
MounjaroTirzepatide16$22,620
EliquisApixaban19$15,613
Arnuity ElliptaFluticasone Furoate15$2,550
Gabapentin46$1,515
Albuterol Sulfate HfaAlbuterol Sulfate38$878
Atorvastatin Calcium71$862
Levothyroxine Sodium84$638
Bupropion XlBupropion Hcl13$435
SynthroidLevothyroxine Sodium12$411
Valsartan12$396
Duloxetine Hcl11$390
Amlodipine Besylate50$280
Rosuvastatin Calcium28$270
Sertraline Hcl19$258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$13$22,77724 claims
Lilly USA, LLCMounjaro$203$22,62016 claims
PfizerEliquis$84$15,61319 claims
GSKArnuity Ellipta$167$2,55015 claims
AbbVieSynthroid$434$41112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →